📅 2026 Update: Changes in Drug Prescribing and Telehealth Services

Since the original article was written, there have been important updates in U.S. drug law and telehealth services. The extension of telemedicine flexibilities allows more access to controlled substances, making it easier for patients to receive necessary medications. The article continues further down the page, covering the foundational aspects of drug laws and services.

🏥 Telemedicine Flexibilities Extended

The U.S. Department of Health and Human Services (HHS) and the DEA have extended telemedicine flexibilities for prescribing controlled substances through December 31, 2026. This change allows registered practitioners to prescribe Schedule II-V medications via telehealth without needing an in-person visit.

This extension aims to improve access to care for patients who may have difficulty visiting a healthcare provider in person.

💊 Permanent Buprenorphine Telemedicine Rule

On January 17, 2025, a final rule was issued by the DEA and HHS, making telemedicine flexibilities for prescribing buprenorphine permanent. Buprenorphine is a key medication for treating opioid use disorder. This rule ensures that patients continue to have access to this critical treatment option through telehealth, which can be more convenient and accessible.

🧠 Strengthening Mental Health Parity

The Mental Health Parity and Addiction Equity Act (MHPAEA) saw final rules released on September 9, 2024. These rules enhance parity between mental health, substance use disorder benefits, and medical benefits. Effective November 22, 2024, these changes require health plans to treat mental health and substance use disorder benefits equally with medical benefits, ensuring better access for those needing treatment.

⏳ Processing Times for Telehealth Prescriptions

Processing times for telehealth prescriptions for controlled substances can vary by provider. Some services may offer same-day consultations, while others could take several days to schedule. Buprenorphine treatment initiation also depends on provider availability and patient readiness, affecting how quickly patients can start essential treatments.

📌 Key Updates Summary

  • 🏥 Telemedicine flexibilities for controlled substance prescriptions extended through December 31, 2026.
  • 💊 Permanent telemedicine rule for buprenorphine established on January 17, 2025.
  • 🧠 MHPAEA final rules enhance mental health and substance use disorder benefit parity effective November 22, 2024.
  • ⏳ Processing times for telehealth prescriptions vary widely by provider.

💡 Tips for Navigating Drug Prescribing and Telehealth

Reviewing your personal situation with an attorney can provide guidance tailored to your needs.

🔍 Understand Telehealth Eligibility

To be eligible for telehealth prescriptions of controlled substances, patients must have a video consultation with a DEA-registered practitioner. This step is crucial for the practitioner to assess the patient's health needs and determine if a prescription is appropriate.

💲 Check Costs for Telehealth Services

Costs for telehealth consultations for controlled substances can vary significantly. Some platforms may charge per consultation, while others offer subscription models. It's important to verify costs with individual providers before proceeding.

📝 Complete Required Forms

Patients seeking buprenorphine treatment via telemedicine should complete any required intake forms. This helps the provider understand the patient's medical history and current condition during the virtual consultation.

⏰ Be Prepared for Processing Times

Processing times for telehealth prescriptions can differ by provider. Patients should be aware that some platforms may offer immediate consultations, while others might require more time to schedule an appointment.

📜 Stay Informed on Regulations

Understanding the latest regulations surrounding telehealth and controlled substances is essential. Telemedicine flexibilities are in effect until December 31, 2026, and it’s important to stay updated on any changes that may affect access to medications.

🏆 Services Ranked by User Reviews (2026)

This section covers services relevant to drug prescribing and telehealth options. These services are evaluated based on user reviews from Trustpilot as of October 2026. The ratings can change, and customer experiences may differ.

It's essential to consider various factors when assessing these services.

🥇 1. Hims & Hers Health

Hims & Hers Health has a Trustpilot score of 3.0. This service is known for offering online healthcare services, including prescription medications and personal care products. However, customers have reported issues with customer service and concerns regarding product effectiveness.

🥈 2. LifeStance Health

LifeStance Health holds a Trustpilot score of 4.0. This company specializes in mental health services, including therapy and psychiatry, with telehealth options available. Despite its strengths, some reviewers mention inconsistent service quality and challenges with appointment availability.

🥉 3. Talkiatry

Talkiatry has a Trustpilot score of 2.4. This service offers online psychiatry and medication management with flexible scheduling. However, it has been noted for limited insurance coverage and variability in clinician quality, which may affect patient experience.

4️⃣ Direct Meds

Direct Meds has a Trustpilot score of 4.6. This service provides telehealth for GLP-1 medications, including compounded semaglutide and tirzepatide. Reviewers appreciate the quality verification process, but there may be limitations regarding insurance acceptance and potential medication side effects.

🆓 Free Resources for Support

The U.S. Department of Labor offers resources related to the Mental Health Parity and Addiction Equity Act (MHPAEA). Additionally, the Substance Abuse and Mental Health Services Administration (SAMHSA) provides a national helpline for individuals seeking information on treatment for mental health and substance use disorders.

🔎 Factors to Compare in Service Selection

  • 📈 Trustpilot score and review count.
  • 💬 Types of services offered related to drug prescribing.
  • 🏥 Availability of telehealth options.
  • 💲 Cost structure for consultations and prescriptions.
  • 📞 Customer service reputation and support options.

❓ Frequently Asked Questions

❓ What are the requirements for telehealth prescriptions?

To receive telehealth prescriptions for controlled substances, patients must have a video consultation with a DEA-registered practitioner who can assess their medical needs.

🚑 Can I receive buprenorphine treatment via telehealth?

Yes, buprenorphine treatment is available through telemedicine. Patients must find a provider who offers this service and complete any necessary intake forms.

📅 How long do telehealth consultations take to schedule?

Scheduling times for telehealth consultations can vary by provider. Some may offer same-day appointments, while others may take several days.

🔍 What types of medications are classified as controlled substances?

Controlled substances include medications like Adderall and Ambien. These drugs have varying potential for abuse and are categorized into different schedules by the DEA.

📞 Where can I find free resources for substance use disorder treatment?

The Substance Abuse and Mental Health Services Administration (SAMHSA) has a national helpline available at 1-800-662-HELP (4357) for those seeking information and treatment referrals.

🏥 What changes have been made to the Mental Health Parity Act?

Recent rules strengthen parity between mental health, substance use disorder benefits, and medical benefits. This ensures that health plans cannot impose stricter limitations on mental health services than on medical services.

⚖️ Recent Court Cases on Drug Law and Policy

There have been various recent court rulings that impact drug law and policy, particularly regarding telehealth and controlled substances. These rulings reflect changing interpretations of regulations and their implications for access to medications.

For more recent rulings, browse more rulings on the news page.

End of October 2026 Update





What is Tequin?



Tequin, or its generic name Gatifloxacin, is an antibiotic developed developed by Kyorin Pharmaceutical Company in Japan and licensed in the United States by Bristol-Myers Squibb that inhibits bacterial enzymes for the treatment of respiratory tract infections.In 2006 Bristol-Myers Squibb stopped manufacture of Tequin after the FDA issued a "black box" warning requirement on all labels associated with Tequin.

Tequin Overview



Side effects



A famous study published by the New England Journal of Medicine in 2006 linked Tequin to diabetes and it was recommended that the drug be issued a "black box" warning.  A "black box" warning is considered to be the FDA's most preventative measure for warning physicians and patients about the use of a product.  The warning consists of a black box design on the label of the product that indicates that the drug has a significant risk of serious or even life-threatening conditions. 

Side effects of Tequin use include dizziness, hyperglycemia, hypoglycemia, erratic heartbeat, liver injury, nausea and fainting.  The major side effect of Tequin is diabetes and diabetes related conditions such as diabetic ketoacidosis and diabetic coma. 



Government Regulations



In 2006 the FDA issued a "black box" warning on all oral forms of Tequin.  Since the FDA put in the regulation the product has been taken off the market and throughout the world companies have begun to lift their forms of Gatifloxacin from their shelves. 



Lawsuits

Although no claims have been made in the United states, legal action against Tequin has been formally filed in the Canadian Court System. In Canadian class action suit Bristol-Myers Squibb settled with plaintiffs for $5 million for failure to warn against conditions that include blood sugar disorders.  One man in the United States is suing Bristol-Myers Squibb for personal injury after he took 3 doses of Tequin and went into a diabetic coma due to an extreme case of hypoglycemia that he blames on the drug.